title: Provider-verified HPV vaccine coverage among a national sample of Hispanic adolescent females.
abstract: BACKGROUND
  Hispanic females have the highest cervical cancer incidence rate of any racial or ethnic group in the United States, yet relatively little research has examined human papillomavirus (HPV) vaccination among this fast-growing population. We examined HPV vaccination among a national sample of Hispanic adolescent females.
  
  
  METHODS
  We analyzed provider-verified vaccination data from the 2010-2011 National Immunization Survey-Teen for Hispanic females ages 13 to 17 years (n = 2,786). We used weighted logistic regression to identify correlates of HPV vaccine initiation (receipt of one or more doses), completion (receipt of three doses), and follow-through (receipt of three doses among those who initiated the series).
  
  
  RESULTS
  HPV vaccine initiation was 60.9%, completion was 36.0%, and follow-through was 59.1%. Initiation and completion were more common among older daughters and those whose parents had received a provider recommendation to vaccinate (all P < 0.05). Completion was less common among daughters who had moved from their birth state (P < 0.05). All vaccination outcomes were less common among daughters without health insurance (all P < 0.05). Vaccination did not differ by parents' preferred language (all P > 0.05), although intent to vaccinate was higher among Spanish-speaking parents (P < 0.01). Spanish-speaking parents were more likely to indicate lack of provider recommendation (20.2% vs. 5.3%) and cost (10.9% vs. 1.8%) as main reasons for not intending to vaccinate (both P < 0.05).
  
  
  CONCLUSIONS
  Many Hispanic females have not received HPV vaccine. Several factors, including provider recommendation and health insurance, are key correlates of vaccination.
  
  
  CONCLUSIONS
  HPV vaccination programs targeting Hispanics are needed and should consider how potential barriers to vaccination may differ by preferred language.
authors.affiliation: Authors' Affiliations: Division of Cancer Prevention and Control, College of Medicine; Comprehensive Cancer Center; College of Public Health, The Ohio State University, Columbus, Ohio; UNC Gillings School of Global Public Health; and Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
authors.forename: Paul L
authors.initials: PL
authors.lastname: Reiter
authors.forename: Kunal
authors.initials: K
authors.lastname: Gupta
authors.forename: Noel T
authors.initials: NT
authors.lastname: Brewer
authors.forename: Melissa B
authors.initials: MB
authors.lastname: Gilkey
authors.forename: Mira L
authors.initials: ML
authors.lastname: Katz
authors.forename: Electra D
authors.initials: ED
authors.lastname: Paskett
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Smith
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D007722:Health Knowledge, Attitudes, Practice; D006630:Hispanic or Latino / Q000706:statistics & numerical data*; D006801:Humans; D007348:Insurance, Health; D008875:Middle Aged; D009367:Neoplasm Staging; D027383:Papillomaviridae / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D010290:Parents / Q000523:psychology; D011379:Prognosis; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination
chemical_list: D053918:Papillomavirus Vaccines